(Q34994161)

English

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

M Schmidt

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

M E Scheulen

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

C Dittrich

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

P Obrist

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

N Marschner

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

L Dirix

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

M Schmidt

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

D Rüttinger

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

M Schuler

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

C Reinhardt

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A Awada

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

24 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

275-282

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

EpCAM (CD326) finding its role in cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Frequent EpCam protein expression in human carcinomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Prospective identification of tumorigenic breast cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Identification and expansion of human colon-cancer-initiating cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Identification of pancreatic cancer stem cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Prospective identification of tumorigenic prostate cancer stem cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

First-line Herceptin monotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Novel endpoints and design of early clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP314

21 January 2018

Identifiers

10.1093/ANNONC/MDP314

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34994161&oldid=1966907242"